IOBT
IO Biotech IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.45M
P/E Ratio
—
EPS
$-1.34
Beta
0.89
52W High
$2.79
52W Low
$0.03
50-Day MA
$0.27
200-Day MA
$0.95
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About IO Biotech Inc
IO Biotech Inc. is a clinical-stage biotechnology firm focused on pioneering innovative immunotherapy solutions to bolster the immune response against cancer. Utilizing its novel immune-oncology platform, the company aims to stimulate and enhance the body’s innate defenses to target tumor cells. With a robust pipeline of therapeutic candidates progressing through clinical trials, IO Biotech is well-positioned to meet pressing unmet needs in oncology, particularly for solid tumors. The company's dedication to rigorous scientific research underscores its potential to transform the standards of cancer treatment and significantly improve patient outcomes.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | $-2.59M |
| EBITDA | $-91.80M |
| Operating Margin | 0.00% |
| Return on Equity | -240.50% |
| Return on Assets | -88.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.01 |
| Price-to-Book | 2.54 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 1.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $71.95M |
| Float | $38.31M |
| % Insiders | 6.63% |
| % Institutions | 46.74% |
Analyst Ratings
Consensus ($2.18 target)
1
Buy2
Hold1
SellData last updated: 4/7/2026